As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An over-all partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- relapsed/refractory lymphomas